Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Slides:

Advertisements

Similar presentations

Figure 1 Schematic representation of idiopathic nephrotic syndrome,

Advertisements

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 2 Pathology of scleroderma renal crisis

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 The epigenetic landscape mediates the interplay between stressors and renal dysfunction Figure 1 | The epigenetic landscape mediates the interplay.

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Role of the kidney in glucose homeostasis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Volume 59, Issue 4, Pages (April 2001)

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 2 Prevention of antigen–antibody

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

cardiovascular and renal systems

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Loss of the glycocalyx leads to podocyte and kidney injury

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Volume 78, Issue 5, Pages (September 2010)

BTG2 regulates gluconeogenic gene expression in diabetic mouse models

Nat. Rev. Nephrol. doi: /nrneph

A: Chemical structure of pterosin A

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic nephropathy (DN) Figure 1 | Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic nephropathy (DN). The standard chemical and genetic diabetes platforms do not typically recapitulate the main features of human DN, with mild kidney involvement characterized by microalbuminuria and minimal structural changes. Combining genetic stressors with diabetes platforms on susceptible genetic backgrounds has led to the development of accelerated models of DN, which tend to have higher levels of albuminuria and more severe glomerular pathology, including glomerulosclerosis. AMDCC, Animal Models of Diabetic Complications Consortium; STZ, streptozotocin. Azushima, K. et al. (2017) Modelling diabetic nephropathy in mice Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.142